On March 25, 2020, Elevar Therapeutics, a biopharmaceutical company specializing in promising therapies for unmet medical needs in cancer, announced an agreement with Swedish-based Oasmia Pharmaceutical AP, a pharmaceutical company engaged in the field of human and veterinary oncology. Wilson Sonsini Goodrich & Rosati advised Elevar Therapeutics in the transaction.

Under the terms of the agreement, Elevar has obtained global rights for Apealea®, except in Nordics, Russia, and certain countries in Eastern Europe. Apealea®, a non-cremophor formulation of the well-known chemotherapeutic agent placlitaxel, has been approved by the European regulatory authorities for use in combination with carboplatin for the treatment of adult patients with certain cancers.

The team of Wilson Sonsini attorneys advising Elevar Therapeutics was led by partners Ian Edvalson and Jason Skolnik.

For more information, please see Elevar Therapeutics’ press release.